Researchers continue to excited about the medication , a groundbreaking dual agonist showing significant data in early trials for body management. It acts by targeting several pathways : GLP-1 and GIP, these, when activated , help control cravings and boost calorie burn. Initial findings indicate noteworthy body loss and possible advantages for pat